Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis | SpringerLink
VENCLEXTA® (venetoclax tablets) | VIALE-A Trial Overall Survival Data
Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma | Anticancer Research
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer
Survival Analysis in R
Metastasectomy and Targeted Therapy for Patients With Spinal Metastases of Renal Cell Carcinoma | International Journal of Spine Surgery
View Image
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Dosisphere - Boston Scientific
Kaplan-Meier estimates of median progression-free survival (PFS, dotted line) and overall survival (OS, straight line) for all patients (N = 46).
IMFINZI® (durvalumab) Efficacy & Clinical Trials for ES-SCLC
NEJM on Twitter: "In women with advanced endometrial cancer, the median progression-free survival was 7.2 months with lenvatinib plus pembrolizumab and 3.8 months with chemotherapy; the median overall survival was 18.3 months
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer
VYXEOS® Efficacy - Phase 3 Trial Data vs 7+3 | VYXEOS® (daunorubicin and cytarabine)
Median overall survival (mOS) and median progression-free survival... | Download Scientific Diagram
Ambiguities in computing the median survival time. - FAQ 44 - GraphPad
Survival Analysis
PADCEV® (enfortumab vedotin-ejfv) Efficacy in Patients with la/mUC
Median Overall Survival (mOS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Kaplan-Meier curves for overall survival. The median overall survival... | Download Scientific Diagram
survival - Time to event analysis - median (IQR) is <75% experience event - Cross Validated
Overall survival curve. Median overall survival time was 8.2 months.... | Download Scientific Diagram
Kaplan-Meier survival analysis
Cancers | Free Full-Text | Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience
